I-O small molecules could be next big thing, reckons Gilead

25 June 2019

Kinase inhibitor specialist Carna Biosciences (TYO: 4572 ) has agreed an R&D deal with California’s Gilead Sciences (Nasdaq: GILD), based around the development of small molecule compounds in immuno-oncology.

Gilead will gain global rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target, for $20 million and up to $450 million in milestones, plus royalties.

The company has been looking to fill the gap left by falling sales in its hepatitis C business, and access to Carna’s proprietary lipid kinase drug discovery platform could help. Carna’s shares rose 16.45% to 1,062 yen following the announcement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK